Retlirafusp alfa
Highest phase reached
Phase 3
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Protein
- Drug name
- Retlirafusp alfa
- drug retlirafusp alfa
- Drug: Retlirafusp alfa
- IMMUNOGLOBULIN G4 (52-GLYCINE, 57-PHENYLALANINE, 227-PROLINE, 233-ALANINE, 234-ALANINE, 446-ALANINE), ANTI-(HUMAN PROGRAMMED DEATH-LIGAND 1) (HUMAN-MUS MUSCULUS MONOCLONAL SHR-1316 .GAMMA.4-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER ((GGGGS)4G) FUSION PROTEIN WITH 20-136-TYPE II TRANSFORMING GROWTH FACTOR .BETA. RECEPTOR (HUMAN ISOFORM 1), DISULFIDE WITH (85-GLUTAMIC ACID) HUMAN-MUS MUSCULUS MONOCLONAL SHR-1316 .KAPPA.-CHAIN, DIMER
- immunoglobulin g4 52 glycine 57 phenylalanine 227 proline 233 alanine 234 alanine 446 alanine anti human programmed death ligand 1 human mus musculus monoclonal shr 1316 gamma 4 chain fusion protein with peptide linker ggggs 4g fusion protein with 20 136 type ii transforming growth factor beta receptor human isoform 1 disulfide with 85 glutamic acid human mus musculus monoclonal shr 1316 kappa chain dimer
- retlirafusp alfa
- Retlirafusp alfa
- Retlirafusp Alfa
- retlirafusp alfa [INN]
- Retlirafusp alfa [WHO-DD]
- Retlirafusp alfa Injection
- retlirafusp alfa inn
- retlirafusp alfa who dd
- shr 1701
- Shr 1701
- SHR-1701
- SHR-1701 injection
- SHR-1701 Injection
- shr1701
- SHR1701
- CAS registry numbers
- 2395839-91-3
- ChEMBL ID
- CHEMBL5095383
- FDA ingredient codes (UNII)
- JP6N6TA92L
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- retlirafusp alfa
- Type
- Antibody
- Drug name stem
- -fusp
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Binding
- Action type
- Binding
- Target
- programmed cell death 1 ligand 1
- Gene symbol
- programmed cell death 1 ligand 1
- Action
- Binding
- Action type
- Binding
- Target
- TGFβ3
- Gene symbol
- TGFβ3
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Hodgkin Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Melanoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Lung Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0008903
- Subject identifier
- D008175
- Condition
- Nasopharyngeal Carcinoma
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0015459
- Subject identifier
- D000077274
- Condition identifier
- EFO_0000181
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000183
- Condition identifier
- EFO_0000574
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0002618
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0000544
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0003210
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003219
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005008
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005036
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005070
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005097
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005105
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005192
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005580
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006519
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007256
- Condition identifier
- MONDO_0008170
- Highest recorded phase
- 2
And 7 more, listed on the interactive page.
- NCT03710265
- NCT03774979
- NCT04324814
- NCT04679038
- NCT04282070
- NCT05020925
- NCT04355858
- NCT04407741
- NCT04560244
- NCT04580498
- NCT04699968
- NCT04937972
- NCT05132413
- NCT05177497
- NCT04624217
- NCT04650633
- NCT04884009
- NCT05106023
- NCT05896046
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (64)
- A Clinical Study of SHR-1701 Combined With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Siewert Type II Adenocarcinoma of the Esophagogastric Junction
- A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC
- A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
- A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer
- A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer
- A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer
- A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer
- A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors
- A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer
- A Trial of SHR-1701 in Subjects With Advanced Solid Tumors
- A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC
- A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC
- A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients
- A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment
- A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
- Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC
- An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging
- An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
- Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
- Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer
In development for (10)
- Breast cancer Phase 2
- Exocrine pancreatic carcinoma Phase 1
- Head and neck squamous cell carcinoma Phase 2
- Hodgkins lymphoma Phase 1
- Lung cancer Phase 2
- Lymphoma Phase 1
- Melanoma Phase 2
- Nasopharyngeal carcinoma Phase 1
- Neoplasm Phase 1
- Non-small cell lung carcinoma Phase 3